Complement inhibitory and anticoagulant activities of fractionated heparins
References (35)
The relationship of molecular weight and sulfate content and distribution to anticoagulant activity of heparin preparations
Carbohyd. Res.
(1974)- et al.
Covalently bound conjugates of albumin and heparin: synthesis, fractionation and characterization
Thromb. Res.
(1983) - et al.
Involvement of membrane-associated sialic acid in the resistance of sheep erythrocytes to lysis by mouse complement
Immunol. Lett.
(1981) - et al.
Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes
J. Immunol. Methods
(1980) - et al.
Effects of immunological adjuvants on the mouse complement system. I. The inability of the polyanion heparin to act as an adjuvant is paralleled by inefficient alternative complement pathway inhibition
Int. J. Immunopharmac.
(1983) - et al.
Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrobin III
Thromb. Res.
(1977) - et al.
Mode of interaction of different polyanions with the first (C1, CI), the second (C2) and the fourth (C4) component of complement. III. Inhibition of C4 and C2 binding site(s) on Cls by polyanions
Immunochem
(1976) - et al.
A postulated mechanism for heparin's potentiation of Cl inhibitor function
Mol. Immunol.
(1982) - et al.
Separation of high and low-activity heparin species by affinity chromatography on immobilized antithrombin III
FEBS. Lett.
(1976) - et al.
High-activity heparin: Chain length, affinity for antithrombin and anticoagulant activity
Arch. Biochem. Biophys.
(1982)
Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin
Thromb. Res.
(1976)
Heparin: an old drug with a new paradigm
Science
(1977)
Mechanism of the anticoagulant action of heparin
Molecular and Cellular Biochemistry
(1982)
Modulation of the formation of the amplification convertase of complement, C3bBb, by native and commercial heparin
J. Exp. Med.
(1978)
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b
J. Exp. Med.
(1979)
Pharmacological activities of heparins obtained from different tissues
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase
J. Clin. Invest.
(1981)
Cited by (25)
Detection of surface bound complement at increasing serum anticoagulant concentrations
2008, Colloids and Surfaces B: BiointerfacesAntithrombin and first complement protein recognize the same active heparin fraction
2002, Thrombosis ResearchDesign of a new type of coating for the controlled release of heparin
1997, Journal of Controlled Release
Copyright © 1984 Published by Elsevier Ireland Ltd.